Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter

  --Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021-- --VERU-111 Phase 1b Clinical Trial Results Accepted for Presentation at European Society for Medical Oncology 2020 Congress -- --Company to Host

August 13th, 2020|
Go to Top